TREATMENT OF X-LINKED SEVERE COMBINED IMMUNODEFICIENCY VIA EX VIVO GENE THERAPY USING A LENTIVIRAL VECTOR COMBINED WITH NON-MYELOABLATIVE CONDITIONING

dc.contributor.authorEligwe, Linda N.
dc.contributor.departmentHood College Biology
dc.contributor.programBiomedical and Environmental Science
dc.date.accessioned2024-10-22T13:26:43Z
dc.date.available2024-10-22T13:26:43Z
dc.date.issued2011-03
dc.description.abstractIn the light that lentiviral vectors have been deemed more efficient and safer at transducing hematopoietic stem cells making them the most promising option for SCID gene therapy, the project will explore a potential gene therapy treatment for X-linked SCID using a lentiviral vector.
dc.format.extent27 pages
dc.genreMock Grant Proposal
dc.identifierdoi:10.13016/m2acoa-0rni
dc.identifier.urihttp://hdl.handle.net/11603/36687
dc.language.isoen_US
dc.titleTREATMENT OF X-LINKED SEVERE COMBINED IMMUNODEFICIENCY VIA EX VIVO GENE THERAPY USING A LENTIVIRAL VECTOR COMBINED WITH NON-MYELOABLATIVE CONDITIONING
dc.typeText

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Eligwe, Linda N.pdf
Size:
11.16 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.65 KB
Format:
Item-specific license agreed upon to submission
Description: